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Aging has been associated with an increase in muscle dysfunction and weakness. We found a decrease in muscle camitine with age [Biochem. 
Biophys. Res. Commun., 161 (1989) 1135-l 1431. Prolonged oral administration to both young (2-month-old) and adult (7-month-old) mice with 
L-camitine increased its content in blood by 50%. The levels of carnitine in skeletal and heart muscle of old treated animals became higher than 
in untreated mice of the same age. However, this extensive restoration did not reach the maximum values present in skeletal muscle of young mice. 
Our findings indicate that an alteration of the camitine carrier in the sarcolemma could be responsible for the decrease with age of camitine in 
skeletal but not in heart muscle. 
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1. INTRODUCTION 
We reported decreased concentrations of carnitine in 
muscle of both old mice and humans [l]. However, the 
levels of carnitine in blood, liver and brain were not 
decreased with age [ 11. Although carnitine can be totally 
synthesized in mammals, there are some metabolic and 
pathological circumstances where the endogenous yn- 
thesis is insufficient. In some of those situations, the oral 
administration of L-carnitine has been reported as bene- 
ficial to re-establish the depleted levels of the compound 
[2-71. In relation to aging, administration of acetylcar- 
nitine has been claimed to improve age-related eficits 
and cognitive function in aged rats [8,9] and humans 
[lo], but it is not known if carnitine supplementation 
could avoid skeletal muscle carnitine reduction. The 
objective of this work was to determine if a prolonged 
oral administration of carnitine could prevent the mus- 
cle carnitine decrease with age. 
2. MATERIALS AND METHODS 
Male Swiss albino mice (Interfauna Iberica, Barcelona, Spain), fed 
a standard diet with a protein content of 18% (Sanders, Spain), were 
used. The animals were treated and killed in a manner consistent with 
the guide of the care and use of laboratory animals of the European 
Community. Groups of 75 animals each, of 2-month-old and Il-month- 
old, mice were maintained for as long as 5-10 months drinking a 
solution of L-camitine (13 mmol/l in tap water) as the sole drinking 
fluid. The same number of animals of each age were maintained on 
drinking tap water alone, as controls. Six animals of each group were 
placed in metabolic cages, two per cage, and the urine was collected 
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every 24 hours in 250 ~1 of 1.2 M perchloric acid. Mortality was not 
statistically different in any camitine-treated group as compared to 
controls of the same age. At indicated intervals blood serum was 
collected. The animals were killed and heart and hind-limb skeletal 
muscle were removed, frozen in liquid nitrogen and stored below 
-7O’C for less than 20 days. Esterified camitine was measured after 
alkaline hydrolysis of the samples and free camitine was determined 
[1 11. Creatinine was determined by the calorimetric test of Boehringer. 
L-Camitine was a commercial preparation from Sigma-Tau (Spain) 
and deoxycamitine was a gift from Dr. N. Siliprandi (Dpto. di Chimi- 
ca Biologica, Universita degli Studi di Padova, Italy). 
Staristical analysis. Results are reported as mean ? S.D. and the 
significance of differences between groups were determined using the 
Student’s t-test. 
3. RESULTS AND DISCUSSION 
Fig. 1 depicts the concentration of camitine in muscle 
of young and adult mice fed on camitine, compared 
with untreated animals of the same age. The concentra- 
tion of free camitine in skeletal muscle of controls de- 
creased steadily with age. The decrease was very sharp 
during the first six months, reaching a plateau at 8-9 
months. Thus, the concentration of camitine at 9 
months of age was approximately half that at 2 months 
of age. The daily supplementation of L-camitine in the 
drinking water of young mice did not stop the decrease 
in free muscle camitine for the first month of admini- 
stration. However, by this time the supplementation of 
L-camitine resulted in a stabilization of carnitine (at 
70% of the initial levels of the young group). Notably, 
the same increase in muscle camitine was also reached, 
when the administration of L-camitine was started later 
(even at 7 months of age, see Fig. 1). 
Fig. 2 shows the concentration of free camitine in 
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Fig, 1. Concentration of free carnitine in muscle of young and adult 
mice treated orally with carnitine. Free carnitine was measured in
hind-limb muscle of mice at different ages. Animals were treated orally 
with 13 mmoY1 L-camitine starting from either: two months of age (A, 
l filled symbols) or from 7 months of age (B, l filled symbols). The 
control group (open symbols) was not treated with carnitine. Arrows 
indicate when camitine treatment was started. Results are the mean 
value k SD. of 5-10 animals. (*) Treatment effect: treated values 
significantly different from untreated group of the same age (P < 
0.001). (a) Age effect: untreated group values significantly different 
from young untreated group (2-month-old) (P < 0.001). 
heart of young and adult mice treated with L-carnitine. 
Although the levels of carnitine in heart decreased 
slightly with age (levels in l-year-old mice were -80% 
of those of 2-month-old animals; with a net decrease of 
180 nmol/g tissue), treatment of both young and old 
animals with carnitine produced an increase in heart 
(Fig. 2), above the free carnitine levels in young controls 
and prevented the decrease in older mice. 
Table I shows the levels of carnitine in serum and 
urine of young, adult and old animals after being fed 
L-carnitine for up to 5 months. The amount of L-car- 
nitine ingested daily was 1.37 + 0.27 mmol/kg body 
weight. There was no significant difference between 
young and adult animals, in the amount ingested. Only 
in the 12-month-old mice was there a slight decrease, 
which could explain the decrease in carnitine excretion 
in urine. In all treated animals there was an increase in 
plasma carnitine levels, up to I.5fold of the starting 
levels, and in urine excretion. Urinary excretion of both 
free and esterified carnitine of mice fed L-carnitine was 
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Fig. 2. Free carnitine content in heart of young and adult mice treated 
orally with L-camitine. The animals studied and statistical analysis 
were the same as in Fig. 1. Results are the mean + S.D. of 5-10 
animals. 
higher in young animals than in the older. From the 
data of esterified carnitine excreted in the urine, of par- 
ticular interest is the -5-fold higher elimination, under 
basal conditions (no carnitine treatment), by the old 
group over the younger, although the total amount of 
carnitine excreted was quite similar in the two groups. 
It seems possible that older animals need to excrete 
more acyl compounds which have not been oxidized in 
the mitochondria; carnitine would facilitate their trans- 
port across cellular membranes and subsequent elimina- 
tion in urine, implying a detoxifying role for carnitine 
in old animals. 
As shown, the response to carnitine treatment was 
different in skeletal from cardiac muscle. While heart 
reached young levels of carnitine, or higher, after less 
than one month of carnitine administration, in skeletal 
muscle those were always below the 70% of young con- 
centrations. In some muscle carnitine deficiencies, it has 
been reported that carnitine administration failed to 
raise skeletal muscle levels, even though the plasma con- 
centrations were elevated, claiming an impairment of 
carnitine transport into muscle cells [12-141. 
The hydroxylation of deoxycarnitine to carnitine is 
restricted to liver and kidney [15]. Other tissues, includ- 
ing skeletal and cardiac muscles, are entirely dependent 
on carnitine uptake from the blood. These tissues do 
export deoxycarnitine to the hydroxylating organs. The 
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existence of a sarcolemmal translocator for carnitine 
has been demonstrated in in vitro and in vivo experi- 
ments [16-181. It was shown that an exchange occurs 
bidirectionally, in a ratio close to l:l, between de- 
oxycarnitine and carnitine. Although under physiologi- 
cal conditions the exchange in muscle will be between 
endogenous deoxycamitine and external carnitine, it 
was demonstrated by Sartorelli et al. [18] that the in- 
traperitoneal administration of high doses of deoxycar- 
nitine will revert the direction of interchange, inducing 
a massive exit of free camitine from the tissues, propor- 
tional to the rate of this carrier, and an entry of de- 
oxycarnitine. Of the total carnitine pool in the body, 
98% is in skeletal muscle. Thus, the rate of increase of 
carnitine levels in urine immediately after deoxycar- 
nitine injection will reflect the activity of the sar- 
colemma carnitine/deoxycarnitine carrier. 
4/1 , , , , , , , 
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As shown in Fig. 3, the administration of deoxycar- 
nitine (intraperitoneal injection of 1 mmol deoxycar- 
nitine per kg body weight), to either young (Z-month- 
old) or old (l-year-old) mice, produced an immediate 
excretion of free carnitine in the urine. On the first day 
after the injection of deoxycamitine the excretion of free 
carnitine was significantly slower in old than in young 
mice (46 pmollmg creatinine in the 2-month-old mice vs. 
3 pmol/mg creatinine in the 12-month-old mice; Fig. 3, 
note log scale). The extent of such elimination was much 
greater in young than in old animals, although on the 
2nd day carnitine excretion in the young was nearly 
Fig. 3. Carnitine excretion in urine of young and adult mice injected 
intraperitoneally with deoxycarnitine. Mice 2-month-old (~1) and 12- 
month (0) were injected i.p. with 1 mmol of deoxycarnitine/kg body 
weight, on the day indicated by the arrow. Free carnitine was deter- 
mined in the urine. Values are shown for several days following the 
injection. Data are the mean of 4 experiments. 
Table I 
Serum and urine carnitine concentrations in mice treated with L-carnitine 
Age of mice Carnitine levels 
Controls 
(untreated mice) 
(a) 
Period of treatment with L-camitine 
1 -week 5-months 
(b) (cl 
2-month-old 
Serum *molil) 
Urine @mollmg treat.) 
Free 
Esterified 
7-month-old 
Serum &molIl) 
Urine @moUmg treat.) 
Free 
Esterified 
12-month-old 
Serum @mol/l) 
Urine @moUmg treat.) 
Free 
Esterified 
38.1 +_ 3.4 
0.415 + 0.053 
0.052 + 0.013 
35.3 + 3.1 
0.280 + 0.065’ 
0.200 f 0.034’ 
36.4 f 3.7 
0.140 f 0.032’ 
0.250 I!I 0.027’ 
55.2 f 5.9* _ 
18.0 f 1.02* _ 
6.2 f 0.58* 
52.3 +_ 1.3* 49.9 * 1.5* 
12.2 + 0.87*+ 13.2 + 0.58*+ 
4.1 + 0.77*+ 3.8 + 0.12*+ 
_ 58.8 + 7.0* 
_ 11.2 f 0.43*+ 
_ 3.2 f 0.39*+ 
The data given for free and esterified camitine excreted in urine are referred to the creatinine content in the urine. Values are the mean + S.E. 
of 6 animals for serum and the mean f S.E. of 6 ammals for 5 consecutive days for urine. The age effect has been indicated by ‘(P < 0.001): 
statistically significant difference versus 2-month-old group (group ‘a’ for controls and group ‘b’ for all treated groups). The treatment effect has 
been indicated by *(P < 0.001): each treated group was referred to controls of the same age. 
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basal, while in the older it was about 1 pmol/mg crea- 
tinine, and was maintained above basal levels for a 
week. 
The data shown indicate that the decrease in skeletal 
muscle carnitine with age may be due to a functional 
alteration of the carrier responsible for the entry of 
carnitine into the myocyte. However, a partial restora- 
tion of carnitine levels can be achieved after 1 month of 
oral administration, at any age. Another implication of 
our observations is the potential detoxifying role of car- 
nitine in old individuals, facilitating the excretion of 
acyl compounds. 
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